This trialtests an experimental drug to find the most effective dose to treat prostate cancer that has spread. It uses a 3+3 design to determine the max tolerated dose.
- Prostate Cancer
1 Primary · 5 Secondary · Reporting Duration: through study completion, average of 12 months
4 Treatment Groups
PCUR-101 Dose Escalation
1 of 4
PCUR-101 Dose Expansion Cohort 1
1 of 4
PCUR-101 Dose Expansion Cohort 2
1 of 4
PCUR-101 Dose Expansion Cohort 3
1 of 4
48 Total Participants · 4 Treatment Groups
Primary Treatment: PCUR-101 Dose Escalation · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Male Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are applicants still being considered for this research endeavor?
"As indicated by records on clinicaltrials.gov, the hunt for participants is still underway. The trial was initially publicized on March 30th 2021 and recently updated as of October 20th 2022." - Anonymous Online Contributor
Has research on PCUR-101 Dose Expansion Cohort 3 been conducted previously?
"Presently, there are 371 ongoing studies exploring PCUR-101 Dose Expansion Cohort 3 with 102 of those trials being in the Phase 3 stage. Most experiments for PCUR-101 Dose Expansion Cohort 3 take place out of Duarte, California though a remarkable number of 17,427 locations host clinical trials related to this topic." - Anonymous Online Contributor
What is the projected number of participants for this trial?
"Affirmative. Clinicaltrials.gov documents that this research trial is still searching for participants since its first posting on March 30th 2021, with the last update taking place October 20th 2022. 48 applicants are required from a single location to complete the study." - Anonymous Online Contributor
What medical condition does PCUR-101 Dose Expansion Cohort 3 usually address?
"PCUR-101 Dose Expansion Cohort 3 is a viable course of action for treating thyroiditis, ulcerative colitis, and various malignant tumors." - Anonymous Online Contributor
Has the PCUR-101 Dose Expansion Cohort 3 been granted official clearance by the FDA?
"The safety of PCUR-101 Dose Expansion Cohort 3 was rated at a 1 due to it being in the initial stages of development, meaning there is limited evidence on its efficacy and safety." - Anonymous Online Contributor